Emerging Data on Novel Psychoactive Substances and Clinical Effects

Emerging Data on Novel Psychoactive Substances and Clinical Effects Aegis launched an extensive and industry-leading testing menu of Novel Psychoactive…

Designer Opioids and Benzodiazepines

Novel Psychoactive Substances (NPS) are a diverse group of synthetic substances created to mimic the effects of scheduled or illicit drugs which vary significantly…

Synthetic Cannabinoids and Synthetic Stimulants

Novel Psychoactive Substances (NPS) are a diverse group of synthetic substances created to mimic the effects of scheduled or illicit drugs; however, they…

Expansion of Oral Fluid Testing of Behavioral Health Drugs

Aegis’ oral fluid testing menu has been expanded to allow providers the option to test for many additional medications and/or illicit drugs. The enhancement…

Review of New InterAct Rx Analyte Positivity

In 2015, Aegis Sciences Corporation began to seek out a way to expand the clinical information that could be provided through definitive testing.  With…

Broaden your Understanding: Benefits of the InterACT Rx™ Expansion

In 2015, Aegis Sciences Corporation began to seek out a way to expand the clinical information that could be provided through definitive testing.  With…

Introduction to Pharmacogenetic (PGx) for Pain Management

Aegis offers pharmacogenetic testing focusing on medication/gene pairs that are supported by clinical guidelines, FDA-approved labeling, or clinical studies…